|
|
Article: Cardium Gains Wound Healing Technology Via TRC Purchase.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
In its third acquisition since it received its initial funding last fall, Cardium Therapeutics Inc. bought the assets of the Tissue Repair Co., which includes a wound healing technology and a lead product candidate to treat diabetic ulcers.
Privately held TRC will become a subsidiary of Cardium, which paid $1 million, assumed $120,000 in liabilities and agreed to provide an additional $1 million upon advancing the lead candidate, Excellerate, into a Phase II study. A DNA-activated collagen gel, Excellarate is formulated with an adenovector delivery carrier encoding human platelet-derived growth factor-B and designed for topical ...
Related newspaper, magazine, and journal articles:
|
|
Article: TRC Acquires Leading Infrastructure Firm.
Business Wire;
October 10, 2001 ;
700+ words
... ... Conn.--(BUSINESS WIRE)--Oct. 10, 2001 TRC Companies, Inc. (NYSE:TRR) announced today the ... leading transportation infrastructure firm, into the TRC family of companies. For TRC's fiscal year ending June 30, 2001, SITE is expected ...
|
|